This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) provides $1,640,169 to Synvivia, Inc. over a 2-year period from December 2024 to November 2026. The funding supports the validation of Synvivia's platform for identifying cyclic peptides that can dramatically increase the yield and quality of adeno-associated virus (AAV) vectors manufactured for gene therapy. The key products and services to be delivered include: 1) demonstrating that Synvivia's peptide discovery library contains compounds that improve AAV production across multiple serotypes, 2) validating lead peptides to enhance vector yield and quality at bioreactor scale, and 3) verifying that AAV vectors produced through the peptide-enhanced manufacturing process perform better than standard vectors in in vivo studies. This work is expected to substantially improve AAV vector production, reduce manufacturing costs, and enhance the affordability and safety of AAV-based gene therapies.
Generated 2/25/25, 5:04 AM